Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

An open-label randomized multicentre Phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2-positive advanced gastric cancer.
trastuzumab
BO18255 (ToGA)
NCT01041404
HER2-positive metastatic breast cancer
Phase 3
 
January 2014

Powered by ideaPoint, Inc.